Rethinking Clinical Trials

AUGUST 30, 2023

In the 18 months of the trial, there were not see changes in the quantitative outcomes that were measured. 552 unique patient participated in the trial. Patients completed a dashboard survey, which gave the study a lot of qualitative measures. I am still optimistic that we will see some improvements in the outcomes we specified.

Trials 143

Trials Clinical Research Coordinator Medicine Clinical Trials 143

Roots Analysis

JANUARY 28, 2024

Velocity: Big Data needs to be handled promptly as businesses generate data at an unprecedented speed, driven by the growing adoption of Internet of Things (IoT), and technologies, such as RFID tags, sensors, and smart meters are used to deal with the high velocity of data in real-time. It is loosely arranged into categories using meta tags.

Big Data 40

Big Data Medicine Marketing Clinical Trials 40

Delveinsight

DECEMBER 3, 2020

Roche receives FDA authorization for the quantitative COVID-19 antibody test. The FDA nods for the Elecsys Anti-SARS-CoV-2 S quantitative antibody test that runs on Roche’s cobas e analyzers, follows its September launch in Europe after receiving a CE mark. of the time and negative results 99.98% of the time, as per Roche.

Gene Therapy 52

Gene Therapy Gene Antibody Research 52

Roots Analysis

AUGUST 28, 2022

These platforms, although widely adopted, require tissue fixation and are therefore not capable of providing fundamental information about cellular interactions and biomarkers quantitative assessment.

Genome 52

Genome Genomics RNA Genome Project 52

XTalks

JANUARY 19, 2024

This biological variability adds complexity, but with that complexity comes the power to choose the targets, the tags and the payloads and select combinations appropriate to the patient to personalize that therapy. There is also potential for using several radiotherapies in combination therapies.

DNA 66

DNA Radiology FDA Approval Development 66

Drug Discovery World

NOVEMBER 9, 2023

After the plenary keynote session, there will be a keynote presentation by Mark McCoy, PhD, Principal Scientist, Quantitative Biosciences, MSD, on higher-order structure, behaviour, and interactions of novel biotherapeutics. Thereafter, there will be two presentations followed by two luncheon presentations.

Engineer 52

Engineer Antibody Protein In-Vivo 52

Pharmaceutical Technology

MARCH 17, 2023

GlobalData calculates these risk scores by evaluating several qualitative and quantitative factors to establish the quality of conditions and the level of stability of the market access environment encountered by pharmaceutical companies in each country. Click here to watch this webinar and access the presentation.

Marketing 257

Marketing Drugs Research Analyst Manufacturing 257